|Other Names||Ubiquitin-associated protein 1, UBAP-1, Nasopharyngeal carcinoma-associated gene 20 protein, UBAP1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP8828a was selected from the N-term region of human UBAP1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Component of the ESCRT-I complex, a regulator of vesicular trafficking process. Binds to ubiquitinated cargo proteins and is required for the sorting of endocytic ubiquitinated cargos into multivesicular bodies (MVBs). Plays a role in the proteasomal degradation of ubiquitinated cell-surface proteins, such as EGFR and BST2.|
|Cellular Location||Cytoplasm, cytosol. Endosome. Note=Predominantly cytosolic Recruited to endosomes as part of the ESCRT-I complex|
|Tissue Location||Ubiquitous. Highly expressed in heart, brain, placenta, lung, liver, skeletal muscle and pancreas|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
UBAP1 is a member of the UBA domain family, whose members include proteins having connections to ubiquitin and the ubiquitination pathway. The ubiquitin associated domain is thought to be a non-covalent ubiquitin binding domain consisting of a compact three helix bundle. This particular protein riginates from a gene locus in a refined region on chromosome 9 undergoing loss of heterozygosity in nasopharyngeal carcinoma (NPC). Taking into account its cytogenetic location, this UBA domain family member is being studies as a putative target for mutation in nasopharyngeal carcinomas.
Qian,J., et.al., J. Cancer Res. Clin. Oncol. 127 (10), 613-618 (2001)Qian,J., et.al., Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao 33 (2), 147-152 (2001)
If you have any additional inquiries please email technical services at email@example.com.